Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
~16 mi.
(Chelyabinsk,
Russia,
+176 more cities)
Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 2644)
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
~16 mi.
(Chelyabinsk,
Russia,
+226 more cities)
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 0565)
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)
~16 mi.
(Chelyabinsk,
Russia,
+147 more cities)
Chelyabinsk Regional Clinical Center Oncology and Nuclear Medicine ( Site 0741)
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)
~16 mi.
(Chelyabinsk,
Russia,
+158 more cities)
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1913)
Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)
~16 mi.
(Chelyabinsk,
Russia,
+131 more cities)
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1816)
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)
~16 mi.
(Chelyabinsk,
Russia,
+145 more cities)
Chelyabinsk Regional Clinical Oncology Dispensary ( Site 2014)
Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)
~16 mi.
(Chelyabinsk,
Russia,
+105 more cities)
Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212)